Stay updated on Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.

Latest updates to the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical trial record describes a phase II study combining pembrolizumab with postoperative radiotherapy for high-risk cutaneous squamous cell cancer of the head and neck. It includes the study design, eligibility criteria, outcome measures, and record details.SummaryDifference48%

- Check17 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedAn NIH banner announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) across federal agency content and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe site footer revision identifier changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check38 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedRevision: v3.7.0 was added. A number of study document attachments were removed from the Study Documents section, including the Informed Consent Form (2019-12-04) and the Study Protocol/Statistical Analysis Plan PDFs.SummaryDifference18%

Stay in the know with updates to Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.